key: cord-0769516-7otrg2f7 authors: Bahadori, Maryam; Mowla, Ashkan title: Re: Tenecteplase for thrombolysis in stroke patients: Systematic review with meta-analysis date: 2021-06-01 journal: Am J Emerg Med DOI: 10.1016/j.ajem.2021.05.079 sha: 742ee3857e995ab20484ed62ec70a7d16f27006a doc_id: 769516 cord_uid: 7otrg2f7 nan Re: Tenecteplase for thrombolysis in stroke patients: Systematic review with meta-analysis Dear editor, We read with great interest and appreciate the systematic review and meta-analysis by Oliveria et al. entitled "Tenecteplase for thrombolysis in stroke patients: Systematic review with meta-analysis". The authors concluded that intravenous Tenecteplase has several advantages over Alteplase, namely higher rate of arterial recanalization leading to better neurological outcome, lower cost, and better pharmacological profile, including being more specific for fibrin and longer half-life. As far as safety, there were no advantages determined by the rate of symptomatic intracerebral hemorrhage incidents and 3-month mortality rate [1] . Although we fully agree with Oliveria et al. notes, we believe that during the coronavirus disease of 2019 (COVID-19) pandemic, intravenous Tenecteplase administration could have additional potential therapeutic and preventive benefits. Cerebral vascular events such as arterial stroke and cerebral venous sinus thrombosis have been shown to be associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection possibly due to a hypercoagulable state and vascular endothelial dysfunction [2] [3] [4] [5] [6] [7] [8] [9] [10] , or an indirect consequence of severe illness [11] . Approximately 1-3% of COVID-19 patients experienced stroke, which was shown to be in association with the illness severity [12] . Time is a well-known critical factor in determination of the neurological outcome of acute ischemic stroke (AIS) patients either by thrombolytic agents or interventional mechanical thrombectomy. American Stroke Association guidelines endorse providing faster thrombolytic therapy from the symptom onset and shorter door to needle time (DTN) [13] [14] [15] . With certain COVID-19 restrictions and protocols, particularly stay-at-home policies and social distancing, particularly in the elderly, the timing to seek medical attention in the case of stroke has been shown to be negatively impacted, and highly time-sensitive therapeutic measures for the treatment of AIS may not take place in a timely fashion [16] Moreover, after presenting to the emergency departments, time-consuming infection control and preventive measures such as screening for COVID-19, etc. might contribute to increase DTN [13] . A recent metanalysis showed that DTN in AIS has been significantly longer during the pandemic, which is concerning [17] . Although these preventive measures are essential in protection against the virus transmission, they could potentially negatively influence the AIS treatment outcomes [18] . In addition, access to COVID-19 test results might not be available until after AIS treatment initiation at times. This could potentially increase the risk of exposure of the emergency department's medical staff and other patients to the asymptomatic virus carriers. Hence, we believe using intravenous Tenecteplase in treating patients with AIS is a forward step toward reducing the exposure of health care workers to potentially SARS-CoV-2 infected patients and decreasing the risk of virus transmission. Tenecteplase requires almost 2 min to be prepared and injected in a single dose, while Alteplase needs more than an hour to be administered. Also, unlike Alteplase, Tenecteplase does not require an additional intravenous line for an infusion pump, and it avoids the need for hospital staff to check the infusion pump repeatedly. In addition, in some centers, Alteplase is being used to treat acute respiratory distress syndrome associated with SARS-CoV-2. The increases in demand and interruption in the supply of Alteplase has caused Alteplase to be less accessible worldwide [13, 19] . All these reasons have made Tenteplase a strong alternative for alteplase during pandemic. We do appreciate Oliveria and colleagues, providing us with a great systematic review and meta-analysis and pointing out the potential advantages of using Tenecteplase over Alteplase. However, we believe that health care facilities and providers should consider intravenous Tenecteplase administration for AIS during the Pandemic. None. Tenecteplase for thrombolysis in stroke patients: systematic review with meta-analysis Cerebral venous sinus thrombosis might be under-diagnosed in the COVID-19 era. eNeurologicalSci Cerebral venous sinus thrombosis associated with SARS-CoV-2; a multinational case series Neurologic compromise in COVID-19: a literature review Risk of stroke in hospitalized SARS-CoV-2 infected patients: a multinational study Letter regarding 'Neurointervention for emergent large vessel occlusion strokes during the COVID-19 pandemic Cerebral venous sinus thrombosis associated with COVID-19: a case series and literature review SARS-CoV-2 and stroke characteristics: a report from the multinational COVID-19 stroke study group Neurological complications of coronavirus infection; a comparative review and lessons learned during the COVID-19 pandemic COVID-19-related acute ischemic stroke in young adults: what is the optimal antithrombotic regimen for secondary prevention? SARS-CoV-2 is a culprit for some, but not all acute ischemic strokes: a report from the multinational COVID-19 stroke study group Unusual pattern of arterial macrothrombosis causing stroke in a young adult recovered from COVID-19 Re: the choice of intravenous thrombolysis for acute ischemic stroke under COVID-19 infection Increased success of single-pass large vessel recanalization using a combined stentriever and aspiration technique: a single institution study Delays in door-to-needle time for acute ischemic stroke in the emergency department: a comprehensive stroke center experience Stroke care during the COVID-19 pandemic; a global challenge A metaanalysis of the global impact of the COVID-19 pandemic on stroke care & the Houston Experience Ischaemic stroke associated with COVID-19 and racial outcome disparity in North America Stroke thrombolysis with tenecteplase to reduce emergency department spread of coronavirus disease 2019 and shortages of alteplase